The morbidity and mortality of vaccinepreventable diseases among older adults are high. Despite the benefits of elderly vaccination, vaccination rates remain low and especially among some minority groups. Specific strategies for improving the rate of vaccination have been developed for medical offices and clinics, hospitals, and other health care institutions. There are vaccines that are recommended routinely for the elderly while other vaccines are recommended in certain circumstances. Knowing the indications, contraindications, and adverse reactions to the recommended vaccines for the elderly is very important to the primary care physicians.
I
nfectious diseases, particularly influenza and pneumonia, are the fifth leading cause of death among older adults. 1 Immunization is one of the most effective means of preventing disease, disability, and death from infectious diseases. By the time most people reach old age, they have been immunized or exposed to many disorders. Nonetheless, they still need immunizations.
Despite the benefits of elderly vaccination, vaccination rates remain low and especially among some minority groups. Influenza vaccination coverage among adults ages Ͼ65 years is 65% which remain below the Healthy People 2010 objective of 90% coverage nationwide. Despite increase in the pneumococcal vaccination coverage among adults ages Ն65 years from 1997 to 2005, 25% of older adults have reported never having received pneumococcal vaccine. 2 Strategies for increasing vaccination rates among older adults are summarized in Table 1 . 3 In this review we will focus on the routinely recommended vaccinations for elderly individuals (Table 2).
Influenza Vaccine
Although influenza is a very common, moderate, and self-limited viral infection, it could be seriously complicated in elderly. Approximately 90% of influenza-related deaths occur among adults ages Ն65 years. 4 In the United States, the number of influenzaassociated deaths has increased in part because the number of older persons is increasing, particularly persons ages Ͼ85 years. 5 Influenza-related deaths can result from pneumonia and from exacerbations of cardiopulmonary conditions. Influenza and its complications can be prevented with either influenza vaccination or antiviral prophylaxis with neuroaminidase inhibitors. Prevention of influenza with neuroaminidase inhibitors is only supportive to the vaccine because of its lower cost-to-benefit ratio.
Immunity to the surface antigens, particularly the hemagglutinin, by inducing specific antibody production reduces the likelihood of infection and severity of disease if infection occurs. 6 The effectiveness of inactivated influenza vaccine depends primarily on the age and immunocompetence of the vaccine recipient, and the degree of similarity between the viruses in the vaccine and those in circulation. Older persons might have lower postvaccination antibody titers than healthy young adults and can remain susceptible to influenza virus infection and influenza-related upper respiratory tract illness. 7 In the 40% to 60% of elderly patients in whom the influenza vaccine produces the desired immunity, an effective immune response can be mounted within 10 to 14 days of vaccination. 8 Prevaccination titers and the number of previous influenza vaccinations have been identified as factors that influence postvaccination titers. Having one or more vaccinations over the previous 4 years confers greater reduction in mortality than first-time immunization. 9 Among older persons who reside in nursing homes the vaccine can be 50% to 60% effective in preventing influenza-related hospitalization or pneumonia, 80% effective in preventing influenza-related death, and 30% to 40% effective in preventing influenza illness. 10 However, the effectiveness of influenza vaccine in community-dwelling elderly is modest. 11 Moreover, economic studies of influenza vaccination in persons older than 65 years conducted in the United States have reported overall societal cost savings. 5 There are 2 types of licensed influenza vaccines in the United States: inactivated influenza vaccine and live attenuated inhaled influenza vaccine. Live attenuated inhaled influenza vaccine (FluMist) has not been approved in persons ages 50 years and older. 5 The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommends annual influenza vaccination for all adults ages 50 years and older and for all residents of long-term care facilities. 5 Immunization should be administered shortly before the anticipated onset of influenza season. In the United States, this usually corresponds to mid-October through mid-November. However, health-care providers should continue to offer influenza vaccine during December and throughout the influenza season, even after influenza activity has been documented in the community.
The committee also recommends vaccination for persons who could transmit influenza to elderly patients, such as healthcare personnel, employees of long-term care facilities, providers of home care to people at high risk, and household contacts (including children). Vaccination of healthcare workers has been associated with fewer deaths among nursing home patients. 12 Inactivated influenza vaccine is most commonly associated with mild local reactions such tenderness at vaccination site. Systemic symptoms (eg, fever, malaise, myalgia, and headache) are rare among vaccinated older adults. Immediate, presumably allergic, reactions (eg, hives, angioedema, allergic asthma, and systemic anaphylaxis) rarely occur after influenza vaccination. These reactions probably result from hypersensitivity to residual egg protein or thimerosal, which is a mercurial antibacterial agents acting as a preservative. The currently licensed inactivated influenza vaccine has either no or minimal amount of thimerosal mercury, Ͻ1.25 h Hg/0.5 mL dose, except the 5.0-mL multidose vial which contains approximately 25 h Hg of mercury as a preservative. 5 Persons with a history of severe hypersensitivity, such as anaphylaxis, to eggs should not receive influenza vaccine. 5 Evidence for a causal relation of Guillian-Barre syndrome (GBS) with influenza vaccine is unclear. The potential benefits of influenza vaccination in preventing serious illness, hospitalization, and death among older adults substantially outweigh the possible risk for experiencing vaccine-associated GBS. 5 
Pneumococcal Vaccine
Pneumococcal disease is a significant cause of morbidity and mortality in the elderly. The case fatality rate of invasive pneumococcal disease increase from 20% for those ages Ն65 years to 40% for those ages Ն85 years. 13 The currently available pneumococcal polysaccharide vaccine (PPV) includes 23 purified capsular antigens. These serotypes in the vaccine represent 85% to 90% of serotypes that cause invasive pneumococcal disease in the United States. 14 Pneumococcal capsular polysaccharide antigens induce typespecific antibodies that enhance opsonization, phagocytosis and killing of pneumococci by leukocytes. The antibodies against pneumococcal antigens remain elevated for at least 5 years in healthy adults. 15 The vaccine protects against invasive pneumococcal diseases such as bacteremia, pneumonia with bacteremia, and meningitis. However, it is less effective for preventing pneumonia without bacteremia. 16 The vaccine should be regarded as 23 different vaccines, rather than 1. Older persons who fail to respond to one serotype may well be protected against infection by the other 22 serotypes. Pneumococcal vaccination was found to cost-saving among adults ages Ն65 years. 17 The vaccine is administered intramuscularly, not intradermally which can cause severe local reaction. It can be administered with other vaccines such as influenza vaccine, but at a separate site. Approxi- Immunization for the Elderly mately one-third of persons who receive pneumococcal vaccine develop mild local side effects such as erythema, pain, or swelling. These local side effects are more common with revaccination with pneumococcal polysaccharide vaccine than with initial vaccination. Systemic reaction such as fever and myalgias are very rare. 14 PPV is recommended for all persons 65 years and older. The ACIP does not recommend routine revaccination with the vaccine every 5 years. The ACIP recommends that persons ages 65 years and older who were initially vaccinated before age 65 should receive only one revaccination provided that at least 5 years have elapsed since the initial vaccination. Furthermore, 1-time revaccination after 5 years is recommended for older adults with chronic renal failure or nephritic syndrome, immunosuppressive conditions such as leukemia, lymphoma, generalized malignancy, organ or bone marrow transplantation, and multiple myeloma, or chemotherapy with alkylating agents, antimetabolites, or highdose, long-term corticosteroids. 18 The 7-valent conjugate pneumococcal vaccine is not recommended for older adults. However, vaccination of young children with the conjugate pneumococcal vaccine has significantly reduced the incidence of pneumonia caused by only the 7 conjugate vaccine serotypes among older adults. 19 
Herpes Zoster Vaccine
Varicella-zoster virus (VZV) causes chickenpox as a primary infection and herpes zoster (HZ) or shingles as a reactivation form of the infection. About 25% of people develop zoster during their lifetime, and there are about 1 million cases of shingles per year. The risk is highest in the elderly, where more that two-thirds of cases occur in people over the age of 50 years. 20 Postherpetic neuralgia (PHN) is the most debilitating complication of HZ. Both the incidence and the duration of postherpetic neuralgia are directly related to increasing age. 21 This increase in the incidence of zoster among older adults is due to a decline in specific cell-mediated immune responses to (CMI) VZV with advancing age. A single dose of live attenuated zoster vaccine substantially reduced the risk for HZ (by 51%) and PHN (by 67%) by increasing VZV-specific CMI in older adults 60 years of age and older over 5.5 years. The vaccine is not 100% effective in preventing HZ. However, cases of HZ and PHN after vaccination appear to be much milder than in those people who develop HZ in the absence of vaccination. The vaccine was more efficacious in preventing HZ among persons who were 60 to 69 years of age than among those who were 70 years or older. On the other hand, the vaccine prevented postherpetic neuralgia to a greater extent among adults ages 70 or more years. 22 VZV vaccination improved the quality of life among older adults because of prevention of both acute pain associated with HZ and postherpetic neuralgia. The cost-effectiveness of the varicella zoster vaccine varies substantially with patient age and often exceeds $100,000 per quality-adjusted life-year saved. 23 The ACIP has recommended people age 60 and older receive zoster vaccine (Zostavax) once regardless of previous history of chickenpox or HZ. 24 It is administered subcutaneously as a single 0.65-mL dose. It must be stored in a freezer with an average temperature of -15°C (5°F) and should not be used if a temperature deviation above -5°C (23°F). 25, 26 If the vaccine is not used with 30 minutes after reconstitution with the supplied diluent, it should be discarded. Although the current recommendation is to vaccinate the elderly once with Zostavax, it is not clear how long the boosted immunity will last and whether an additional booster vaccination will be required. The current vaccine resulted in increased VZV-specific CMI for up to 5 years. 27 It is contraindicated in people with active, untreated tuberculosis and in immunocompromised adults such as those with leukemia, lymphoma, or generalized malignancy and in patients receiving chemotherapy, radiation, and large doses of corticosteroids. The vaccine should not be administered to persons with a history of anaphylactic reaction to gelatin, neomycin, or any other vaccine component. In general, adverse reactions associated with Zostavax are limited to injection-site reactions, such as pain, erythema or swelling, itching, and headache. Rarely, zosteriform rash due to preexisting wild-type virus has been reported at the injection site within the first 42 days after vaccination. Cardiac events occurred more often among the vaccine recipients than among the placebo recipients. 28 
Tetanus Toxoid
Tetanus in the United States is most commonly reported in older persons who are less likely to be adequately vaccinated than younger persons. In 2004, 47% of the 34 cases reported were among persons Ͼ60 years of age. 94% of persons who contract tetanus in the United States are not up-to-date on tetanus vaccination or have never received the primary series. 29 Tetanus toxoid consists of a formaldehyde-treated toxin. There are 2 types of toxoids available, adsorbed toxoid and fluid toxoid and adsorbed toxoid is preferable because of higher and longer standing antitoxin titers. Tetanus toxoid is combined with diphtheria toxoid in the adult vaccine, Td, or with both reduced diphtheria toxoid and acellular pertussis, Tdap. 18, 30 Tdap is not licensed for use among adults ages Ն65 years. Routine boosters are recommended every 10 years for all persons, including older adults 65 years and older, because antitoxin titers approach the minimal protective level by 10 years after the last dose. Although Tdap is the recommended booster vaccine for tetanus in adults ages 19 to 64, Td is still the recommended one for adults 65 or older. 18 In a small percentage of individuals, antitoxin titers fall below the protective level within 10 years of last booster. Therefore, persons who sustain a wound that is other than clean and minor should receive a tetanus booster if more than 5 years have elapsed since their last booster. For individuals who were never vaccinated against tetanus, a primary series of 3 doses is recommended (0 month, 1 month, 6 to 12 months). 18 Local adverse reactions such as erythema and tenderness are common and often self-limited. An extensive local reaction presented 2 to 8 hours after vaccination as extensive painful swelling of injection site is rare. It is more common in adults who have received frequent doses of tetanus toxoid. Brachial neuritis and Guillian-Barre syndrome, although very rare, is associated with Td vaccination. Td is contraindicated in individuals with severe allergic reactions to the vaccine. In these individuals tetanus immune globulin should be considered whenever an injury other than clean minor wound is sustained. 18 
Other Vaccines
The vaccines that are indicated for special circumstances in older adults are summarized in Table 3 . Information for travel-related vaccination can be accessed through CDC website at http://www.cdc. gov/travel.
Conclusion
Vaccination appears to be safe and effective in the elderly. It is routinely recommended for influenza and pneumococcal pneumonia, herpes zoster, and tetanus. Annual influenza vaccination with inactivated vaccine is recommended for all adults 50 years and older. Live attenuated influenza vaccine is not recommended for elderly. PPV is recommended for all persons 65 years and older. Revaccination with PPV every 5 years is not recommended. However, one-time revaccination is recommended if they were vaccinated Ն5 years previously and were ages Ͻ65 years at the time of primary vaccination. Unless contraindicated, all adults ages 60 and older should receive zoster vaccine (Zostavax) once. For all older adult who were never vaccinated against tetanus, a primary series of 3 doses is recommended; otherwise routine boosters are recommended every 10 years. 
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